{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"34.3","value":"17.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Time to progression is measured as the length in time in months from starting therapy until progression, defined as 25% increase in serum IgM from nadir.","dispersionType":"Full Range","groups":[{"description":"Intended therapy consisted of 48 weeks of lenalidomide (25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.","id":"OG000","title":"Lenalidomide and Rituximab"}],"paramType":"MEDIAN","populationDescription":"All enrolled patients","reportingStatus":"POSTED","timeFrame":"34.3 months","title":"Time to Progression","type":"PRIMARY","unitOfMeasure":"months"}